|
Conference Theme For Next Delhi IPC: “Regulation For
Better Healthcare” The next Indian Pharmaceutical Congress
(IPC), scheduled to be held in Delhi from December 12 to 14 under the aegis of
Indian Pharmacy Graduate Association (IPGA), will have ‘Pharma Vision 2020:
Regulations for better healthcare’ as the central theme.
“Everything is going on smoothly as far as preparations are concerned. We have
finalised sub-committees for all aspects and official travel partner and media
partner were also approved by the committee. Now the central council meeting of
the IPCA by the end of this month will finalise the details on the scientific
sessions,’’ said Nasa, who is also the president of the IPGA. Logo of the event
has also been released and the organisers are expecting minimum 5000 delegates
this time, he added. The LoC is headed by DCGI Dr Surinder
Singh as its chairman while former DCGI M Venkateshwarulu had been named the IPC
president earlier. Different sub-committees were also meeting as and when needed
and preparations were going on in full swing, the organising secretary added.
The previous IPC at Varanasi, hosted by the Department of Pharmaceuticals of the
Banaras Hindu University and attended by over 5000 delegates, had ‘Pharma Vision
2020: product, patient, practice’ as the central theme.
(Ref: Chronicle Pharmabiz dated July 12, 2008)
B Braun
Launches Coroflex Please Drug Eluting Stent In India B
Braun Melsungen AG, Germany, one of the medical devices manufacturing majors,
has launched the next generation ‘drug eluting stent’ (DES) - Coroflex Please -
in India. The Coroflex Please is designed to overcome current procedural
limitations of the first generation DES. “Coroflex Please is a
new generation stent, which is designed to improve safety and efficacy compared
to earlier generation stents. The platform is Coroflex which is a benchmark in
terms of its flexibility and crossing profile, eluted with an effective anti-proliferative
drug ‘Paclitaxel’ and an innovative coating technology. In particular in the
diabetic segment, Paclitaxel seems to have an edge over the other drugs,
however, more clinical studies are conducted to validate the same”, said Dr
Michael Boxberger - director of Clinical Sciences, B Braun Medical Melsungen AG.
Existing data suggest that angioplasty and stenting, particularly drug eluting
stents are considered to be most preferred in coronary artery heart disease and
specially diabetic. This procedure can be of great advantage for the patients
who are reluctant to undergo surgery or unfit for surgery. Interventional
cardiology remains a safe and treatment of choice in selected patients amongst
this group. (Ref: Chronicle Pharmabiz dated July 11, 2008)
HLL, IL&FS Ink Mou For An Integrated Medical Devices And
Diagnostic Manufacturing Park Hindustan Latex (HLL)has
signed a memorandum of understanding (MoU) with Infrastructure Leasing and
Financial Services (IL&FS) for developing an integrated medical devices and
diagnostic manufacturing park (MediPark) at Chengalpet near Chennai, Tamil Nadu.
The 330-acre MediPark would be developed on public-private-partnership basis and
the project outlay for infrastructure development is expected to be around Rs
100 crore. The MediPark will manufacture medical devices,
equipments and medical diagnostics. It will also house a sterilisation centre,
testing and quality control facilities, waste disposal facility, logistics hub
etc. IL&FS, the project consultants, would identify the prospective investors
and provide engineering and financial services. (Ref: 22
Aug, 2008, 0144 hrs IST, ET Bureau) |
